蟾酥注射液治疗晚期卵巢癌临床研究

发布时间：2018-06-09 04:31

本文选题：晚期卵巢癌 + 蟾酥注射液　；参考：《河南中医》2017年05期

【摘要】：目的:观察蟾酥注射液治疗晚期卵巢癌的临床疗效。方法:将78例晚期卵巢癌患者随机分为观察组和对照组,每组各39例。所有患者给予TP方案(紫杉醇+顺铂)进行新辅助化疗,化疗结束后进行肿瘤细胞减灭术,观察组在对照组的基础上给予蟾酥注射液进行治疗。比较两组患者的临床疗效,观察两组患者治疗前后生存质量评分变化情况,检测两组患者治疗前后CA125含量。结果:观察组有效率为82.1%,对照组有效率为66.7%,两组患者临床疗效比较,差异具有统计学意义(P0.05)。两组患者治疗后血清CA125含量明显低于治疗前,且观察组低于对照组,差异具有统计学意义(P0.05);两组患者治疗后生活质量评分显著高于治疗前,且观察组高于对照组,差异具有统计学意义(P0.05)。观察组各项毒副作用发生率均明显低于对照组,差异具有统计学意义(P0.05)。结论:蟾酥注射液治疗晚期卵巢癌疗效确切,安全性较高。
[Abstract]:Objective: to observe the clinical effect of Toad Chun injection in the treatment of advanced ovarian cancer. Methods: 78 patients with advanced ovarian cancer were randomly divided into observation group and control group with 39 cases in each group. All patients were given TP regimen (paclitaxel cisplatin) for neoadjuvant chemotherapy and tumor cell reduction after chemotherapy. The observation group was treated with toad injection on the basis of control group. To compare the clinical efficacy of the two groups, to observe the changes of quality of life score before and after treatment, and to detect the content of CA125 before and after treatment. Results: the effective rate was 82.1 in the observation group and 66.7 in the control group. The difference between the two groups was statistically significant (P 0.05). After treatment, the serum CA125 level of the two groups was significantly lower than that of the control group (P 0.05), and the quality of life score of the two groups after treatment was significantly higher than that of the control group, and that of the observation group was higher than that of the control group. The difference was statistically significant (P 0.05). The incidence of side effects in the observation group was significantly lower than that in the control group, and the difference was statistically significant (P 0.05). Conclusion: Toad injection is effective and safe in the treatment of advanced ovarian cancer.
【作者单位】：中国核工业北京四0一医院;
【分类号】：R737.31

【相似文献】